Tecentriq for Locally Advanced or Metastatic Urothelial Carcinoma

February 13, 2019

Tecentriq (atezolizumab, Genetech)

Indications: Patients with locally advanced or metastatic urothelial carcinoma

  • Not eligble for cisplatin-containing chemotherapy & whose tumors express PD-L1

  • Not eligible for any platinum-containing chemotherapy regardless of PD-L1 status

  • Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy

Dosage

  • Metastatic Urothelial Carcinoma or Previously Treated NSCLC
  • 1200 mg intravenously 60 mins x 3weeks

  • 1200 mg IV over 60 minutes, followed by bevacizumab, paclitaxel and carboplatin, on the same day every 3 weeks x4-6

Contraindications: none

Click here for more prescribing information